H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Synergy Pharmaceuticals Inc (NASDAQ: SGYP) today and set a price target of $7. The company’s shares closed yesterday at $1.70, close to its 52-week low of $1.43.
According to TipRanks.com, Selvaraju is a 2-star analyst with an average return of 0.8% and a 41.6% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as IntelliPharmaCeutics International, Biospecifics Technologies Corp, and EyePoint Pharmaceuticals Inc.
Currently, the analyst consensus on Synergy Pharmaceuticals Inc is Strong Buy and the average price target is $8.25, representing a 385.3% upside.
In a report released yesterday, Canaccord Genuity also maintained a Buy rating on the stock with a $13 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $4.84 and a one-year low of $1.43. Currently, Synergy Pharmaceuticals Inc has an average volume of 3.38M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Synergy Pharmaceuticals, Inc. engages on the development and commercialization of novel gastrointestinal therapies. Its commercial product, plecanatide, is marketed under the trademark name TRULANCE, which seeks to treat adults with chronic idiopathic constipation and irritable bowel syndrome with constipation.
Read More on SGYP:
